<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580957</url>
  </required_header>
  <id_info>
    <org_study_id>060085</org_study_id>
    <secondary_id>CRC-1522</secondary_id>
    <nct_id>NCT00580957</nct_id>
  </id_info>
  <brief_title>The Autonomic Nervous System and the Metabolic Syndrome</brief_title>
  <official_title>The Autonomic Nervous System and the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this proposal is to determine the role of the autonomic nervous system in
      the insulin resistant state associated with obesity and the metabolic syndrome. Obesity
      results from an accumulation of excessive fat deposit due to increase caloric intake or
      decrease energy expenditure, this condition is usually associated with diseases such as
      hypertension or diabetes, a cluster known as the metabolic syndrome. The first step in the
      development of the metabolic syndrome is a resistance to the action of insulin. The mechanism
      underlying insulin resistance in obesity is still unknown, however some investigators have
      proposed that the autonomic nervous system, particularly the increase sympathetic activation
      in obesity may play an important role. We have extensive experience studying the role of the
      autonomic nervous system in the cardiovascular alterations associated with obesity by
      producing complete autonomic withdrawal with a drug named trimethaphan. We propose to use the
      same approach to study the role of the autonomic nervous system in the development of insulin
      resistance in obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to look at the role of the autonomic nervous system, an
      involuntary nervous system that controls your blood pressure, in insulin resistance and the
      metabolic syndrome. Insulin is a substance that helps your body use the sugar in the food
      that you eat. Some people's tissues stop reacting in a normal way to insulin, a condition
      known as insulin resistance. A person with insulin resistance can have other health problems,
      such as obesity, high cholesterol, and high blood pressure. These problems together are
      called the metabolic syndrome. We think that the autonomic or involuntary nervous system
      controls the way your body responds to insulin. This system is changed in obese people, and
      we think that it may cause the insulin resistance. We plan to study this with two drugs
      -trimethaphan and L-NMMA. Neither of these drugs are approved by the Food and Drug
      Administration (FDA), and they will be used for research purposes only.

      Fifty people will take part in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>Last 30 minutes of a two hour insulin clamp</time_frame>
    <description>Glucose infusion rate in mg/kg/min</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Blocked</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intact</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will be used instead of trimethaphan during insulin clamp</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blocked</intervention_name>
    <description>Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance</description>
    <arm_group_label>Blocked</arm_group_label>
    <other_name>Trimethaphan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intact</intervention_name>
    <description>Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance</description>
    <arm_group_label>Intact</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For lean subjects:

          -  21 subjects aged 18-60 yr.

          -  All potential volunteers will have routine blood test to screen for hepatic, renal,
             and hematological abnormalities.

          -  Body mass index &lt; 25Kg/m^2 .

          -  Female volunteers of childbearing potential will undergo HCG pregnancy test at
             screening and again on the study day.

          -  For Obese subjects with metabolic syndrome:

          -  21 subjects aged 18-60 yr.

          -  All potential volunteers will have routine blood test to screen for hepatic, renal,
             and hematological abnormalities.

          -  Body mass index &gt; 30Kg/m^2.

          -  Participants will be enrolled if they met at least three of the following criteria for
             metabolic syndrome (Expert panel, Jama 2001):

               1. Waist circumference &gt;102 cm in men and &gt;88 cm in women

               2. High fasting blood sugar (&gt;110 mg%)

               3. Triglyceride levels &gt;150 mg%

               4. Low HDL cholesterol (&lt;40 mg% for men; &lt;50 mg% for women)

               5. High blood pressure (systolic=130 and diastolic = 85 mmHg) â€¢ Female volunteers of
                  childbearing potential will undergo serum HCG pregnancy test at screening and
                  urine HCG pregnancy test again on the study day.

        Exclusion Criteria:

          -  Pregnant females

          -  Subjects unable to give voluntary informed consent

          -  Subjects on anticoagulant drugs or anemic (anemia defined as Hcto less than 35%)

          -  Subjects with a recent medical illness documented by physicians's visit or detected
             during the screening visit.

          -  Subjects with a history of coronary heart disease.

          -  Subjects with known kidney or liver disease.

          -  Subjects with recent weight loss or consuming low carbohydrate diet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <results_first_submitted>May 29, 2015</results_first_submitted>
  <results_first_submitted_qc>May 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2015</results_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Trimethaphan</mesh_term>
    <mesh_term>Trimethaphan camsylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Blocked</title>
          <description>Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
Blocked: Trimethaphan 4 mg/min IV will be infused for the duration of the study.
L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance</description>
        </group>
        <group group_id="P2">
          <title>Intact</title>
          <description>Saline will be used instead of trimethaphan during insulin clamp
Intact: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Blocked Then Intact</title>
          <description>Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
Blocked: Trimethaphan 4 mg/min IV will be infused for the duration of the study.
L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance</description>
        </group>
        <group group_id="B2">
          <title>Intact Then Blocked</title>
          <description>Saline will be used instead of trimethaphan during insulin clamp
Intact: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="6"/>
                    <measurement group_id="B2" value="43" spread="5"/>
                    <measurement group_id="B3" value="43" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Resistance</title>
        <description>Glucose infusion rate in mg/kg/min</description>
        <time_frame>Last 30 minutes of a two hour insulin clamp</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blocked</title>
            <description>Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
Blocked: Trimethaphan 4 mg/min IV will be infused for the duration of the study.
L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Intact</title>
            <description>Saline will be used instead of trimethaphan during insulin clamp
Intact: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance</title>
          <description>Glucose infusion rate in mg/kg/min</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.3"/>
                    <measurement group_id="O2" value="3.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During and up to 1 hour after finishing the 2 hour insulin clamp.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Blocked</title>
          <description>Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
Blocked: Trimethaphan 4 mg/min IV will be infused for the duration of the study.
L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance</description>
        </group>
        <group group_id="E2">
          <title>Intact</title>
          <description>Saline will be used instead of trimethaphan during insulin clamp
Intact: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Italo Biaggioni, M.D. Professor of Medicine</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>(615) 936-3420</phone>
      <email>italo.biaggioni@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

